Johnson & Johnson announced the commercial launch of its pulsed‑field ablation (PFA) system in Peru on March 16, 2026, marking a key expansion of the company’s cardiovascular portfolio into a new Latin American market.
The PFA technology offers a minimally invasive approach to treating drug‑refractory paroxysmal atrial fibrillation, delivering improved safety, precision and procedural efficiency compared with traditional thermal ablation. Clinical trials such as admIRE and inspIRE demonstrated the system’s ability to achieve durable arrhythmia control while reducing procedural time and complications, providing a strong evidence base for the commercial rollout.
The Peru launch is part of Johnson & Johnson’s broader MedTech expansion strategy in Latin America, supported by initiatives like the “Innovations in Health Equity LatAm” accelerator program. In 2025, the MedTech segment grew 6.1% to $33.79 billion, with the cardiovascular sub‑segment expanding 15.8% to $8.93 billion, driven in large part by recent acquisitions such as Abiomed and Shockwave Medical.
The VARIPULSE™ Platform differentiates itself through full integration with the CARTO™ 3 electroanatomical mapping system, giving J&J a competitive edge over rivals Boston Scientific and Medtronic. This integration enhances procedural efficiency and safety, reinforcing the company’s position in the high‑margin cardiac device market.
By entering the Peruvian market, Johnson & Johnson strengthens its MedTech footprint and positions the PFA platform for broader adoption across Latin America, supporting the company’s goal of accelerating growth in high‑margin MedTech products and diversifying its revenue base beyond pharmaceuticals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.